Chembio Diagnostic Inc (CEMI) - Financial and Strategic SWOT Analysis Review

Chembio Diagnostic Inc (CEMI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description - A detailed description of the company’s operations and business divisions.
Corporate strategy - Analyst’s summarization of the company’s business strategy.
SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
Company history - Progression of key events associated with the company.
Major products and services - A list of major products, services and brands of the company.
Key competitors - A list of key competitors to the company.
Key employees - A list of the key executives of the company.
Executive biographies - A brief summary of the executives’ employment history.
Key operational heads - A list of personnel heading key departments/functions.
Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Chembio Diagnostic Inc (Chembio) develops, manufactures, markets and licenses point-of-care diagnostic (POCs) tests for the detection of infectious diseases including COVID-19, sexually transmitted disease, and fever and tropical disease. The company offers products to prevent the spread of infectious diseases with solutions like Dual Path Platform (DPP). Its DPP technology is used to treat infectious diseases such as HIV, Ebola, syphilis, Zika, malaria and febrile illness. Chembio also offers veterinary diagnostics. The company offers products to medical laboratories and hospitals, governmental, non-governmental organizations, and public health entities, medical professionals and retailers. The company distributes products through a network of distributors worldwide. Chembio is headquartered in Hauppauge, New York, the US.

Chembio Diagnostic Inc Key Recent Developments

Aug 04, 2022: Chembio Diagnostics Reports Second Quarter 2022 Financial Results
May 24, 2022: Chembio Diagnostics Announces Election of Leslie Teso-Lichtman to Its Board of Directors
May 17, 2022: Chembio Diagnostics announces agreement for Reszon Diagnostics International to manufacture Chembio’s HIV 1/2 STAT-PAK assay at Chembio Diagnostics Malaysia facility
Mar 03, 2022: Chembio Diagnostics Reports Fourth Quarter and Full Year 2021 Financial Results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Section 1 - About the Company

Chembio Diagnostic Inc - Key Facts
Chembio Diagnostic Inc - Key Employees
Chembio Diagnostic Inc - Key Employee Biographies
Chembio Diagnostic Inc - Major Products and Services
Chembio Diagnostic Inc - History
Chembio Diagnostic Inc - Company Statement
Chembio Diagnostic Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

Section 2 - Company Analysis

Company Overview
Chembio Diagnostic Inc - Business Description
Product Category: Government Grant Income
Performance
Product Category: License and Royalty Revenue
Performance
Product Category: Product Sales
Performance
Product Category: R&D Revenue
Performance
Geographical Segment: Africa
Performance
Geographical Segment: Asia
Performance
Geographical Segment: Europe and Middle East
Performance
Geographical Segment: Latin America
Performance
Geographical Segment: The US
Performance
R&D Overview
Chembio Diagnostic Inc - Corporate Strategy
Chembio Diagnostic Inc - SWOT Analysis
SWOT Analysis - Overview
Chembio Diagnostic Inc - Strengths
Chembio Diagnostic Inc - Weaknesses
Chembio Diagnostic Inc - Opportunities
Chembio Diagnostic Inc - Threats
Chembio Diagnostic Inc - Key Competitors

Section 3 - Company Financial Ratios

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

Section 4 - Company’s Lifesciences Financial Deals and Alliances

Chembio Diagnostic Inc, Medical Equipment, Deals By Year, 2016 to YTD 2022
Chembio Diagnostic Inc, Medical Equipment, Deals By Type, 2016 to YTD 2022
Chembio Diagnostic Inc, Recent Deals Summary

Section 5 - Company’s Recent Developments

Aug 04, 2022: Chembio Diagnostics Reports Second Quarter 2022 Financial Results
May 24, 2022: Chembio Diagnostics Announces Election of Leslie Teso-Lichtman to Its Board of Directors
May 17, 2022: Chembio Diagnostics announces agreement for Reszon Diagnostics International to manufacture Chembio’s HIV 1/2 STAT-PAK assay at Chembio Diagnostics Malaysia facility
Mar 03, 2022: Chembio Diagnostics Reports Fourth Quarter and Full Year 2021 Financial Results
Jan 05, 2022: Chembio Diagnostics Announces Appointment of Larry Steenvoorden as Chief Financial Officer
Mar 11, 2021: Chembio Diagnostics Reports Fourth Quarter and Full Year 2020 Financial Results
Mar 08, 2021: Chembio Diagnostics Appoints Industry Leader David Bespalko to its Board of Directors
Feb 25, 2021: Chembio Diagnostics to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021

Section 6 - Appendix